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OVERVIEW 
Colorectal cancer (CRC) is the third most common cancer in the world and was listed as the 
fourth most common cancer in South Africa in 2004 1. The average person’s lifetime risk of 
CRC is 5% 2. The incidence of CRC is higher in people aged 50 and older; however, recent 
literature shows an increasing incidence of CRC in patients younger than 50 years 3. Young 
age is considered a poor prognostic factor, these patients usually present with advanced 
stages and more aggressive histopathologic disease. Survival ultimately depends on the stage 
at diagnosis. Five-year survival for localized disease is 90%, 60% for regional disease and 
10% for metastatic disease 3.  
 
Due to lack of recognized screening programs in South Africa, a significant number of 
patients with CRC present to surgical units with complicated colorectal cancer (CCC). These 
complications range from obstruction, perforation, fistula and bleeding and are associated 
with a worse prognosis. Approximately 30% of patients with CRC present with 
complications 4. Of these, 8-10% present with obstruction, and approximately 3% with 
perforation. Morbidity and mortality associated with emergency surgery is very high 5. 
 
Since there is lack of data on CCC in South Africa, this study was undertaken to establish the 
prevalence of CCC among patients presenting to the KwaZulu-Natal teaching hospitals.  
 
The main objectives were (i) to establish the prevalence of CCC in our setting, (ii) to analyse 
and compare the complication rates amongst different racial and age groups in KwaZulu-
Natal, (iii) to determine treatment outcomes, and (iv) to compare our findings to other parts 
of the world. 
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This study was undertaken using collected data from the Colorectal Cancer Database that is 
archived at the University of KwaZulu-Natal’s Department of General Surgery. The ongoing 
database, which commenced in the year 2000, had accrued a total of 1824 patients with CRC 
by the end of 2015.  
 
Four hundred and thirty-one of these patients in this cohort were found to have CCC (23.6%). 
Patient’s demographic details, clinical presentation, complication type and site as well as the 
type of intervention and outcome were reviewed. Interestingly no patients presented with 
bleeding as the cause of CCC.  The complications in this cohort were managed via stent, 
diversion, resection or a combination of these procedures. 
 
From this study of CRC over a 16-year period in KwaZulu-Natal, 23.6% patients presented 
with complications. The male to female ratio was 1.2:1.  
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ABSTRACT 
Background 
Colorectal cancer (CRC) is the third most common +cancer in the world. According to 
National Cancer Registry in 2004, was listed the 4th most common cancer in South Africa. 
The average person’s lifetime risk of CRC is 5%. Majority of CRC is sporadic, with only 
20% associated with inherited and inflammatory bowel disorders. Incidence increases with 
increasing age and genetic mutations. CRC incidence higher in people aged 50 and older. 
Unfortunately the incidence of CRC is escalating in patients younger than 50. Young age is 
considered a poor prognostic factor, usually presenting in advanced stages, with more 
aggressive histopathologic features. Other risk factors depend on lifestyle 
and behaviour (diet, smoking, alcohol, obesity). Survival depends on the stage at diagnosis. 
Five year survival for localized disease is 90%, 60% for regional disease and 10% for 
metastatic disease. Due to lack of recognized screening programs in South Africa, a large 
number of patients with CRC present to surgical units with complications of colorectal 
cancer. Morbidity and mortality associated with emergency surgery is very high. It is 
estimated that about 30% of patients with CRC present with complications such as 
obstruction, perforation, bleeding and fistulas. Of these 8-10% present with obstruction, and 
approximately 3% with perforation. These complications are associated with the worst 
prognosis. 
 
Aim 
There is a lack of data on complicated colorectal cancer in South Africa. The study was 
therefore undertaken in order to establish the prevalence of complicated colorectal cancer 
among patients presenting to the KwaZulu-Natal teaching hospitals. 
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Methods 
This is a retrospective analysis of a prospectively collected data. The on-going KwaZulu-
Natal colorectal cancer database was established in 2000. The database now comprise 1944 
patients with colorectal cancer (CRC). Of these, 448 patients presented with complicated 
colorectal carcinoma and these patients form the basis of this analysis. 
  
Results 
Four hundred and forty eight patients with complicated colorectal carcinoma were accrued 
during the period 2000 - 2016. There were 244 (54.5%) males and 204 (45.5%) female. There 
were 165 Indians, 163 Africans, 92 White and 28 Coloured patients. The mean age at 
presentation was 56.4± 14.4years. Seventy patients (16.1%) were young patients, presenting 
at or under the age of 40 years. A total of 382 (20%) patients presented with malignant 
obstruction, 71 (4%) with perforation and 28 (1.5%) with malignant fistula. Twenty-five 
patients presented with combined obstruction and perforation and eight had combined 
malignant obstruction and fistula. The most common sites for malignant obstruction were 
sigmoid and rectum; the sigmoid colon and caecum were the most common sites for 
perforation and the rectum and sigmoid colon predominated among patients with malignant 
fistula. The majority of the patients presented as stages II, III and IV at 26.3%, 26.6% and 
29.7% respectively. The median follow up period was 11 months for all three groups of 
complications (range 1-180 months for malignant obstruction, 1-94 months for perforation 
and 1-94 months for malignant fistula) 
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Discussion 
 The proportion of patients with complicated colorectal cancer was 23%.The mean age for the 
cohort was 56.4±14.4 years, considerably less than 63-72 years reported in the world 
literature. The age at presentation for Blacks was the youngest being about one to two 
decades younger than the other population groups. Whites were oldest at presentation in 
comparison to other races and their mean age approximated the world literature. These 
population differences in age distribution mimic that seen in the general population of 
patients with CRC in KwaZulu-Natal, where Blacks were a decade younger than the other 
population groups. The proportion of patients presenting with obstructing CRC in this study 
was 20%, it fell within the range of published series and did not differ between races or 
gender. Perforation was the second most common complication (4%) in this study. Contrary 
to obstruction and fistula, perforation seemed to have an equal sex incidence. The 1.5% 
fistula rate in this series compares favourably with the literature.  
In malignant obstruction resection rate was 68% with a five-year survival rate of 70%. 
Patients with perforation had the highest resection rate at 97% and they achieved the best an 
overall five-year survival of 85%. Malignant fistula had the lowest resection rate at 32% and 
the five-year survival was the poorest at 60% compared to the other neoplastic complications 
in this series. 
 
Conclusion 
The prevalence of complicated colorectal cancer in our setting is similar to that reported in 
the literature. The prevalence is the same across all population groups and the sex incidence 
is similar, but the age at presentation is younger in Blacks. The site distribution varied 
according to the complication, with obstruction associated more frequently with left-sided 
disease and fistula involving the sigmoid and rectum.  
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The resection rate was dependent on the type of complication. The resection rate was better 
for malignant perforation and obstruction than malignant fistula. The fistula population also 
had a worst survival rate. Patients who underwent resection had a zero in-hospital mortality 
rate. 
The perforation status did not impact on long-term outcome. Patients with malignant fistula 
appeared to have the worst outcome. Presentation of CCC (and CRC in general) at a younger 
age in our setting in Black patients highlights the need for more research in developing 
countries.  
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CHAPTER 1 
LITERATURE REVIEW 
 
Colorectal cancer (CRC) is reported as the third most commonly diagnosed cancer in males 
and the second in females 1CRC is the third most commonly diagnosed cancer and the third 
leading cause of cancer death in both men and women in the United States 6. The highest 
incidence rates are reported in developed countries such as Australia, New Zealand, Europe, 
and North America. Africa and South-Central Asia report lower rates 7.CRC is said to be the 
second most common cancer in Europe and the incidence is steadily increasing 8. In 2012 the 
annual number of new CRC reported was 447000, and  215000 fatalities in Europe 8. In  most 
Indian cancer registries, the incidence of  CRC is reported to be amongst the lowest in the 
world 9 . However, the incidence rates of CRC in Indian immigrants to the United Kingdom 
and USA are much higher, supporting the concept of life style and dietary habit in the 
causation of  CRC  9. CRC is strongly associated with advanced age, a western-style  diet and 
a sedentary lifestyle 10. Recently, there’s been an increase in the incidence of CRC in patients 
younger than 50 7. The average person’s lifetime risk of developing CRC is approximately 
5% 2. 
 
In most parts of the world, CRC has a higher incidence in men than women.  
The overall mortality rate for CRC has been reported to be 35% higher in men well as the 
incidence of rectal tumours 31% versus 24% in women 11.  
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It is generally accepted that CRC occurs less frequently in underdeveloped countries when 
compared to Western countries 12. CRC is the fifth most common malignancy in Africa  
although it tends to be more common in Northern Africa 13. Epidemiological data on the 
occurrence of cancer in Sub-Saharan Africa (SSA) is sparse, and obtaining  population-based 
cancer survival data is even more difficult due to various logistical difficulties 12. A 
significant number of younger Black patients under the age of 50 are presenting with CRC in 
SSA, unfortunately this has been under-reported in the literature 10. 
 
The majority of  CRCs are sporadic, 50-60% 14. The two most common hereditary syndromes 
include hereditary non-polyposis colon cancer (HNPCC) and familial adenomatous polyposis 
(FAP)14. Diet and lifestyle are important identifiable risk factors in the sporadic cancers; with 
diets high in animal fat, protein, processed food, alcohol and smoking being the most 
commonly cited dietary issues 14.  
 
The stage of the disease at diagnosis is directly proportional to the survival 14.The five-year 
survival for localised disease is reported to be 90%, 68% for regional disease and 10% for 
metastatic disease 11.Interestingly, recent studies have shown  a relative rightward shift in the 
location of colon cancer over the past three decades 11. Also in the last three decades, in the 
US, there has been a change in the racial distribution of the disease with high mortality rates 
seen in Blacks than Whites 6.  
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Graham et al analysed data from 19 different countries in SSA and found the highest 
incidence of CRC to be in Zimbabwe and South Africa12. They also reported the data 
collection systems to be of poor quality; possibly resulting in under reported local statistics 15. 
The incidence of CRC in SSA is said to be higher in males with a  peak incidence  over  the 
age of 75, a crude incidence of 4.04 per 100 000 population 12. Despite poor record keeping 
in SSA these authors noted South African registries to be of the highest quality 15. 
Furthermore, they noted that the rates in different ethnic populations were comparable in 
South Africa due to the  diverse demographic structure 12. Graham et al also found that, in 
SSA, the major anatomical site of CRC was the rectum (46%), followed by the caecum 
(17%).  These trends are similar to those found in the Western World 12.  
 
Studies from as far afield as Western Africa have shown similar trends. Irabor, reported the 
incidence of CRC in Nigeria to be increasing, and that the average annual incidence was 27 
patients per year 16. He also noted that, although the incidence rates were increasing, it was 
still about one tenth of that seen in developed countries.   
 
Irabor hypothesised that this decreased incidence may be due to the different dietary lifestyles 
of many West African nations. Possible cancer protective factors may be present in the staple 
starchy, high-fibre, spicy, peppery foodstuff as well as a diet low in animal protein 16. He 
suggested that geographical location of  West African nations, and their weather, was another 
possible protective factor 16. The same study noted that patients in SSA presented at an 
advanced stage of the disease 16. He attributed this to poverty, lack of local resources and 
poor education.  
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There has been some data focussing specifically on the South Africa population. Cancer 
registry statistics shows an increase in incidence of CRC in South Africa over the last decade 
17. According to the South African National Cancer Registry of 2011, CRC was ranked the 
fifth most common cancer in males and the sixth in females in South Africa  17. Findings by 
Graham et al 12 have shown that, in South Africa, the incidence is highest in Whites, followed 
by the Asian and then Coloured populations, with Blacks having the lowest reported 
incidence 12.  The epidemiology of CRC in White South Africans therefore appears to follow 
the classic Western trend. Moreover, Segal found that, despite the long-established Western 
dietary habits in urbanized South African Blacks living in the Witwatersrand, Black South 
Africans still had a much lower incidence of CRC than White South Africans 18. According to 
the 1993–1995 South African Cancer Registry, in African patients, CRC was responsible for 
2.0% of all cancers 17. Over this period the incidence rates for African males and females 
were 2.1 and 1.6 per 100 000 ‘world’ population. The corresponding rates for White males 
and females were far higher, 24.7 and 19.3, respectively, per 100 000 17, demonstrating that 
the incidence in Blacks was less than one tenth that in Whites. This was despite the three to 
four generations of “westernization” among Blacks. Although international screening 
guidelines exist, there are no set guidelines in South Africa. Despite this a large number of 
cases present to the surgical clinics with complications of CRC, such as tumoral obstruction, 
perforation, and fistula. 19  
 
 
 
 
 
 
15 
 
 
 
CHAPTER 2 
RESEARCH QUESTION 
 
Research question 
What are the clinicopathological trends in patients with complicated colorectal carcinoma 
presenting to KwaZulu-Natal teaching hospitals? 
 
Hypothesis 
The incidence of complicated colorectal cancer is more common in our setting compared to 
the world standard. 
 
Aim 
To establish the prevalence of complicated colorectal cancer in patients presenting to 
KwaZulu-Natal hospitals and to document management outcomes in our setting. 
 
Objectives 
To analyse patients presenting with complicated colorectal cancer over the 16-year period 
from year 2000 to 2015 in KwaZulu-Natal 
To determine the prevalence of complicated colorectal cancer in KwaZulu-Natal 
To establish the clinicopathological patterns of complicated colorectal cancer amongst 
different racial groups in KwaZulu-Natal 
To document treatments and outcomes of colorectal cancer in KwaZulu-Natal 
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CHAPTER 3 
METHODOLOGY 
 
STUDY SETTING 
The study was undertaken at the Colorectal Unit situated at Inkosi Albert Luthuli Central 
Hospital (IALCH), a tertiary referral hospital situated in Durban. The data used were 
extracted from the Colorectal Cancer database archived in the Department of General Surgery 
at the University of KwaZulu-Natal. Patients with CRC are referred from various teaching 
hospitals in KwaZulu-Natal to IALCH where they are seen in the multi-disciplinary clinic 
(MDC). 
 
STUDY POPULATION 
All patients referred with histologically proven CRC are entered into the Colorectal Cancer 
Database. The database was started in 2000 and collection is ongoing. Patients with 
Complicated Colorectal Cancer (CCC) are initially seen at their regional hospital where the 
first surgical intervention is undertaken prior to referral to IALCH for decision-making in the 
MDC. Patients presenting with complete obstruction are managed initially at the base 
hospital. Patients with incomplete obstruction are referred to the Colorectal Unit at IALCH 
for evaluation with regard to further management, which is either a diverting colostomy or 
stent insertion. Population groups were defined as Africans (Blacks, Coloureds, Indians and 
Whites according to the criteria devised by the South African Government.  
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For the purpose of this dissertation, “African” and “Black” are used interchangeably and the 
word “Black” has been used throughout in this manuscript. Patients’ data for this study have 
been extracted from the database between 2000 and 2016. 
 
STUDY DESIGN  
This is a descriptive cohort study involving a retrospective analysis of prospectively collected 
data extracted from the database. Data of all patients with CCC accrued between 2000 and 
2015 were extracted from the database and analysed. Those with subacute obstruction 
underwent investigation such as colonoscopy or contrast enema to make the diagnosis of 
malignant obstruction. The decision to perform a defunctioning colostomy versus stent 
insertion was based on the feasibility of stent insertion. This was a clinical decision. Those 
patients who presented with a complete obstruction underwent emergency exploratory 
laparotomy and the diagnosis of the malignancy was made intra-operatively and confirmed 
with histology. Parameters analysed were age, sex, race, clinical presentation, duration of 
symptoms, co-morbidities, location of tumour, stage of disease, complications, type of 
intervention, histology, resection margins, post-operative complications, oncotherapy and 
follow up.  
 
All patients with CRC are followed up in the Oncology and Colorectal Clinics at IALCH and 
Addington Hospital, Durban. Diagnosis of perforation was made either on the basis of gross 
operative findings and confirmed by histology or entirely on pathologic review of the 
histopathology. A free perforation was defined as a perforation into the peritoneum with 
localized or generalized peritonitis. A contained perforation was defined as perforation into a 
confined space localized by peritoneum, omentum, or bowel.  
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The diagnosis of a malignant fistula was made by virtue of the presence of the fistulous tract 
diagnosed clinically either on imaging or histology. Tumour location was sub-grouped into 
proximal colon, distal colon and rectum. The proximal colon included the caecum, ascending 
colon, hepatic flexure and transverse colon. Distal colon included splenic flexure, descending 
colon and sigmoid colon. Sites documented as ‘recto-sigmoid’ were classified under 
‘rectum’. Complications were classified into three major groups: obstruction, perforation and 
fistula. For the purposes of this study, “bleeding” was regarded as a symptom and was not 
included under “neoplastic complications”. Tumours were staged according to the TNM 
(tumour, node and metastasis) and UICC numeric staging in the CRC database. T stage was 
based on the histology of the resected specimen and the M stage was made at surgery or on 
radiological assessment. For the purposes of analysis the UICC staging was used in this 
dissertation. 
 
 
INTERVENTION 
Obstruction was managed with resection, diverting colostomy, stent insertion or a 
combination of these modalities. All patients with perforation underwent resection. 
Management options for fistula included resection, diverting colostomy or stent insertion. 
The management of the complication was dependent on the patient’s presentation. Patients 
presenting with acute complete obstruction were scheduled for immediate surgery.  
 
 
 
19 
 
The decision on resection versus diverting stoma depended on the resectability of the tumour. 
Patients with sub-acute obstruction were considered for insertion of self-expanding metal 
stent (SEMS). SEMS were used as palliative treatment for malignant colorectal obstruction. 
The term “successful insertion of stent” refers to successful deployment of stent followed by 
relief of symptoms. “Failure of insertion” refers to failure of the stent to deploy. Palliative 
stents were placed in patients who were considered either unfit for surgery or with 
irresectable tumours. Where the tumour was considered to have borderline resectability, a 
stent was inserted as a ‘bridge to surgery’.  
 
Following stent insertion, when patients were considered operable and the tumour 
irresectable, the patients were offered neo-adjuvant therapy and were then re-assessed for 
possible resection. Treatment was considered as palliative if there was either a non-resectable 
tumour, metastatic cancer or patients were physically unfit for curative oncological resection. 
All stents were inserted via colonoscopy under radiological guidance using an image 
intensifier. Boston Scientific Colonic Walls Stents (Boston Scientific, MA, USA) were the stents 
deployed. Procedures were performed under conscious sedation. 
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FOLLOW-UP 
Patients were followed up in the Oncology and Colorectal Clinics at IALCH and Addington 
Hospital. Deaths were established from hospital records or obtained from the Department of 
Home Affairs (South African Government). 
 
DATA MANAGEMENT 
Data were collected on a dedicated proforma and subsequently transcribed onto an MsAccess 
Database. Data were analysed using Ms-Excel, in which different ethnic groups were 
compared. Continuous data are presented as either mean and standard deviation or median 
values (range). One-way analysis of variance (ANOVA) was used to compare ages of the 
different population groups.  
 
ETHICS STATEMENT 
The proposal for this study was reviewed and approved by the University of KwaZulu-
Natal’s Biomedical Research Ethics Committee (Ref: BE246/15). 
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CHAPTER 4 
RESULTS 
 
At the end of 2015, the database comprised 1944 patients with CRC of whom 615 were 
Blacks, 753 Indian, 89 Coloured and 367 White. Of these, 448 patients presented with 
complications (25.1%). When stratified according to population groups 161of the 615 Black 
patients presented with complications (26%), 157 of 753 Indian patients (21%), 25 of 89 
Coloured patients (28%) and 88 of 367 White patients (24%). Of the 431 patients with CCC, 
244 were male and 204 were female resulting in a male to female ratio of 1.2:1. The mean 
age at presentation was 56.4 + 14.4 years with a range from 18 to 92 years. The age 
distribution is shown in Figure 1. The age at presentation peaked in the seventh decade.  The 
average age at presentation was 49.65 + 15.36 years for Blacks, 54.97 + 11.9 years for 
Indians, 54.97 + 11.9 years for Coloureds and 64.47 + 11.63 years for Whites. Seventy 
patients (16.1%) were young, presenting at or under the age of 40 years. The age at 
presentation was similar in all complication categories. The proportion of patients presenting 
with complications aged 40 years or younger was 15.7% for obstruction, 22.9% for 
perforation and 22.25% for fistula. 
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Figure 1 
Age distribution in patients with complicated colorectal cancer. 
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Table I shows the profile of patients presenting with CCC. A total of 382 patients presented 
with malignant obstruction (20%). Perforation occurred in 71 patients (4%) and malignant 
fistula in 28 patients (1.5%). Twenty-five patients presented with combined obstruction and 
perforation and eight had combined malignant obstruction and fistula. One patient presented 
with a diaphragmatic hernia. The CCC group had a slight male preponderance at 54%. When 
looking at individual complications there was a slight male preponderance for obstruction, 
perforation occurred with equal incidence in both sexes and females predominated in patients 
presenting with fistula. The mean age at presentation was highest for obstruction at 56.6 ± 
14.51 and lowest for perforation at 52.4±14.81. The proportion of patients presenting under 
the age of 40 years was lower for obstruction when compared to perforation and fistula. Age 
distribution for the different population groups is shown in Table II. 
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TABLE I 
PATIENT PROFILE OF PATIENTS WITH COMPLICATED COLORECTAL 
CANCER 
 
 Total with 
complications 
Obstruction Perforation Fistula Other 
Overall 
(n=1944) 
448(23.1%) 382 (19.7%) 71 (3.7%) 28 (1.5%) - 
Males 244 212 37 14 1 
Females 204 170 34 14 0 
M:F ratio 1.2:1 1.3:1 1:1 1:1 - 
Mean age 
(years) 
56.4 + 14.4 56.8 + 14.3 52.4 + 14.9 57.5 * 71 
Age range 
(years) 
18-92 18-92 19-82 26-69 71 
< 40 years 70 (15.6%) 57 (15.0%) 17 (23.9%) 6 (22.2%) 1 
> 40 years 378 325 54 22 0 
 
Please note: Some patients had more than one complication. 
*  Median 
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TABLE II 
AGES OF DIFFERENT POPULATION GROUPS PRESENTING WITH 
COMPLICATIONS OF COLORECTAL CANCER 
 
Overall Obstruction 
(mean + SD) 
Perforation 
(mean + SD) 
Fistula 
(median) 
Black 50.55 + 15.87 42.78 + 14.36 43 
Indian 55.55 + 11.66 54.09 + 10.2 61 
Coloured 58.35 + 15.71 59 median 73 
White 64.71 + 11.25 63.78 + 12.87 53.5 
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Site distribution is shown in Table III. The most common sites for obstruction were the 
sigmoid colon and the rectum, with equal frequency at both sites. Following this was the 
caecum and then the ascending colon. The most common site for perforation was the sigmoid 
colon followed by caecum and ascending colon. Among patients with malignant fistula, the 
most common site was the rectum followed by the sigmoid colon. 
 
Staging is shown in Table IV. The majority presented as stages II, III and IV. In patients with 
obstruction, the most common stage was IV followed by II and III respectively. Among 
perforation, the most common stage was III followed by stage II and IV respectively. In 
fistula stages II and IV were similar. 
 
Figure 2 compares staging of the CRC cohort (1824) with the CCC (431) cohort. In patients 
with CCC, there was a higher proportion of patients with stages II, III and IV when compared 
to the overall cohort. Figure 3 shows survival of the whole group of patients and figure 4 
shows survival stratified according to complication. 
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TABLE III 
DISEASE DISTRIBUTION IN PATIENTS WITH COMPLICATED COLORECTAL 
CANCER 
 
Site * Obstruction 
n=382 
Perforation 
n=71 
Fistula 
n=28 
Other 
n=1 
Ascending + 
caecum 
59 (15.5%) 19 (26.8%) 1 (3.6%) 0 
Hepatic flexure 14 (3.7%) 3 (4.2%) 0 1 (100%) 
Transverse 24 (6.3%) 4 (5.6%) 1 (3.6%) 0 
Splenic flexure 22 (5.8%) 3 (4.2%) 0 0 
Descending 30 (7.9%) 5 (6.9%) 0 0 
Sigmoid 120 (31.4%)     28 (39.4%) 9 (32.1%) 0 
Recto-sigmoid 40 (10.5%0 2 (2.8%) 2 (7.1%)  
Rectum 73 (19.1%) 7 (9.8%) 15 (53.6%) 0 
  
* Please note: Some patients had tumour at multiple sites 
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TABLE IV 
STAGING IN PATIENTS MANAGED FOR COMPLICATED COLORECTAL 
CANCER 
 
Stage Overall Obstruction Perforation Fistula 
I 20 (4.5%) 18 (4.7%) 1 (1.4%) 0 (0%) 
II 118 (26.3%) 99 (25.9%) 26 (36.6%) 8 (28.6%) 
III 119 (26.6%) 93 (24.4%) 34 (47.9%) 3 (10.7%) 
IV 133 (29.7%) 125 (32.7%) 9 (12.7%) 6 (21.4%) 
Not staged 58 (13%) 47 (12.3%) 1 (1.4%) 11 (39.3%0 
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Figure 2  
Comparing the stage of disease at presentation of patients with complicated colorectal 
cancer compared to all patients with colorectal cancer (t-CRC = total with CRC; c-CRC 
= total with complications).  
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Figure 3 
Survival of the whole group of patients presenting with complicated colorectal cancer. 
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CHAPTER 4.1 
MALIGNANT OBSTRUCTION 
 
There were 364 patients with malignant obstruction of whom 202 were males, resulting in a 
male to female ratio of 1.3:1. The mean age was 57.2 + 14.9 years. Ages for different 
population groups are shown in Table II. Black patients were a decade younger than the other 
population groups. The most common site was the sigmoid colon followed by the rectum. 
Metastatic disease at presentation occurred in 122 (33.5%). Management of malignant 
obstruction is shown in Table V. A total of 239 patients underwent resection (65.7%). 
Seventy-four percent of patients received a diverting colostomy, nine patients had a 
colostomy post resection. Resection procedures are shown in Table VI.  
 
The most common surgical resection undertaken was a sigmoidectomy followed by right a 
hemicolectomy. Thirty-two patients underwent total colectomy due to either a distended 
proximal colon or multiple lesions and a total of 47 stents were inserted. Two hundred and 
twenty-four patients had R0 resections (95%), 12 had R1 resections and three had R2 
resections. The objective of stent insertion was palliation in 40 patients (85%) and bridge to 
surgery in seven patients (13%). Stent insertion was successful in 41 patients (87%) with 
failure in six patients (13%). One of the six patients (two %) developed a perforation as a 
consequence of the stent insertion. 
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TABLE V 
THE MANAGEMENT OF 382 PATIENTS WITH MALIGNANT COLORECTAL 
OBSTRUCTION 
 
Management  N % 
Resection ab initio 233 - 
Stent followed by resection 5 - 
Colostomy followed by resection 9 - 
Total undergoing resection 247 64.6% 
   
Colostomy ab initio 89 - 
Failed stent -> colostomy 5 - 
Total undergoing colostomy 94 24.6% 
   
Conservative de novo 2 - 
Failed stent -> conservative 1 - 
Total managed  conservatively 3 0.8% 
   
Stent insertion 41 10.7% 
   
Bypass 5 1.3% 
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TABLE VI 
SURGICAL PROCEDURES UNDERTAKEN IN PATIENTS WITH MALIGNANT 
OBSTRUCTION 
 
Procedure N % 
Sigmoid colectomy 75 19.6% 
Right hemicolectomy 1 74 19.3% 
Subtotal colectomy 34 8.9% 
Left  hemicolectomy 2 41                   10.7% 
Transverse colectomy 7 1.8% 
Bypass procedure 5 1.3% 
Abdominoperineal resection 9 2.4% 
Anterior resection 20 5.2% 
No resection  117 30.6 
 
Legend 
1Includes extended right hemicolectomy 
2Includes extended left hemicolectomy 
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CHAPTER 4.2 
MALIGNANT PERFORATION 
 
Seventy-one patients developed perforation, which accounted for 4% of the total cohort of 
patients with CRC.  The male to female ratio was 1.1:1. Mean age was 52.4 + 14.8 years. 
Blacks were the youngest and were one to two decades younger when compared to the other 
population groups. The most common site was the sigmoid colon followed by the ascending 
colon and caecum. Metastatic disease was seen in eight patients (Table IV).  Procedures 
undertaken are shown in Table VI. Perforation occurred at the tumoral site, and was 
contained in the vast majority, free perforation occurred in only two patients.  None of the 
patients presented with localized or generalized peritonitis. The most common site of 
perforation was the sigmoid colon (27) followed by the caecum and ascending colon (19), 
rectum (nine), descending colon (five), hepatic flexure (four) and transverse colon (four). 
Twelve patients (25%) presented with colonic obstruction and the perforation was discovered 
at the time of emergency resection. The remaining patients underwent elective surgery with 
the perforation identified either at operation or on pathology.  
 
Sixty-nine patients had a contained neoplastic perforation and were managed by resection 
(97%). One patient with obstruction presented with a proximal caecal perforation; in this 
patient the tumour was deemed irresectable and a colostomy was fashioned. Another patient 
sustained a colonic perforation proximal to the tumour at colonoscopy. He immediately 
underwent laparotomy and a colostomy was fashioned as the tumour was deemed 
irresectable. There was no postoperative mortality in this group of patients. A total of 61 
patients had R0 resections (88%), seven patients had R1 resections and one had a R2 
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resection. The majority of patients presented as stages II (26, 36.6%) and III (34, 48%). Only 
eight patients presented as stage IV (11.3%) and one as stage I (two %). No patient had 
peritoneal carcinomatosis or peritoneal metastases. Three patients had a resection with 
residual microscopic disease (R-1 resection) at the circumferential margin (6.4%). All 
proximal and distal margins were free of tumour. 
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Table VII 
SURGICAL PROCEDURES UNDERTAKEN IN 71 PATIENTS WITH MALIGNANT 
COLORECTAL CANCER PERFORATION 
 
 
Procedure N % 
Right hemicolectomy 1 25 35.2% 
Sigmoid colectomy               23                   32.4% 
Subtotal colectomy                5 7.0% 
Left hemicolectomy 2                6 8.5% 
Transverse colectomy                3 4.2% 
Abdominoperineal resection                3 4.2% 
Anterior resection                3 4.2% 
No resection               3 4.2% 
 
Legend 
1Included extended right hemicolectomy 
2Includes extended left hemicolectomy 
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CHAPTER 4.3 
MALIGNANT FISTULA 
 
There were 28 patients with malignant fistula (1.5%) identified, 12 were male, resulting in a 
male to female ratio of 1:1.3. The most common site was the rectum followed by the sigmoid 
colon. The median age was 52.4 years. Blacks were one to two decades younger when 
compared to the other population groups. The secondarily involved organs are depicted in 
Table VIII.  Colovesical and rectovaginal fistulae were the most common fistula at 50% and 
39.2% respectively. Fistula management is demonstrated in Table IX. The majority of the 
patients underwent diverting colostomy (64%) and eight underwent resection 28.6%). Table 
X shows the surgical procedures performed to address the malignant fistula. The most 
common procedure was a sigmoid colectomy followed by abdominoperineal resection. Most 
patients with fistula had stage II and IV disease at 28%  and 21% respectively. One patient 
with malignant enterocutaneous fistula underwent conservative management.
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TABLE VIII 
 
SECONDARY ORGANS ON PATIENTS WITH COLORECTAL MALIGNANT 
FISTULAE 
Secondary organ n % 
Bladder 14 50 
Vagina 11 39,2 
Small bowel 3 10.7 
Bladder and small bowel 1 3.6 
Skin 1 3.6 
 
* Some fistulae communicated with more than one organ 
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TABLE IX 
MANAGEMENT OF 27 PATIENTS WITH MALIGNANT COLORECTAL FISTULA 
 
Management N % 
Colostomy 18 64.3 
Total undergoing resection 8 28.6 
    Resection 7  
    Stent followed by 
resection 
1  
Stent only 1 3.6 
Conservation management 1 3.6 
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TABLE X 
SURGICAL PROCEDURES UNDERTAKEN IN PATIENTS WITH CRC 
COMPLICATED BY MALIGNANT FISTULA FORMATION 
 
Procedure N % 
Sigmoid colectomy 5 17.8 
A-P Resection 2 7.1 
Right hemicolectomy 1 3.6 
Extended left hemicolectomy 1 3.6 
No resection  19 67.8 
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CHAPTER 4.4 
FOLLOW-UP 
 
Patients were followed up in the Oncology and Colorectal Clinics in IALCH and Addington 
Hospital. The duration of follow-up varied depending on patients’ adherence on their 
appointments. 
 
Malignant obstruction 
Median follow-up for obstruction was 11 months (range 1-180 months). Twenty-three of the 
patients who underwent resection developed recurrence (9.6%). All 23 developed local 
recurrence, with 8 of these developing additional metastatic disease. After 180 months, the 
overall survival was 60%. One hundred and ninety-one patients died during the follow up 
period of this study. The five-year survival rate was 70% (Figure 4). The median disease free 
interval was 20.5 months (range 9-107 months). Of the 242 patients without metastatic 
disease at presentation, 22 progressed during follow-up (9%). The median progression free 
interval was 13 months (range 8-74 months). Among those who underwent surgery, there 
were no postoperative deaths. 
 
Malignant perforation 
Median follow-up for perforation was 11 months (range 1-94 months). At 140 months, 
overall survival was 85%. Of the 69 patients who underwent resection, 11 developed local 
recurrences (15.7%). Five-year survival for perforation was 85% (Figure 4). The median 
disease free interval was 12.5 months (7-36 months). Of the 63 patients without metastatic 
disease, seven progressed. The median progression free interval was 13 months (range 9-36 
months). 
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Malignant fistula 
Median follow-up for fistula was 11 months (range 1-94 months). At 80 months, 54% of 
patients with fistula had survived. Five-year survival was 60% (Figure 4). Of the nine patients 
that underwent resection, one developed a local recurrence (14%) after an interval of 20 
months. Out of the seven patients undergoing resection, two had R1 resections (28.6%) and 
five had R2 resections (71.4%). Of the 21 patients with no metastatic disease, two progressed 
(10%) after a median interval of 11.5 months. 
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Figure 4 
Survival curves showing survival stratified according to complication.  
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CHAPTER 5 
DISCUSSION 
 
This study investigated patients presenting with CCC, there were a total of 1824 patients with 
CRC identified over a period of 16 years, Four hundred and thirty-one patients (23.6%) 
presented with complications. The mean age for the cohort was 55 years, considerably less 
than the 63-72 years reported in the world literature 2,5.  
 
Interestingly, the age at presentation for Blacks is the youngest reported internationally, being 
about one to two decades younger. White patients were the oldest at presentation in 
comparison with other races and their mean age approximated the world literature. These 
population differences in age distribution mimic that seen in the general population of 
patients with CRC in KwaZulu-Natal, where Blacks were a decade younger than the other 
population groups 20.  
 
Up to 30% of CRCs present with complications, namely obstruction or perforation 4. In the 
majority of cases of CCC surgery is the primary treatment 21. Patients who present with acute 
colonic emergencies are often elderly and frail with multiple comorbidities. Moreover, upon 
emergency presentation, these patients are generally in a poor physical condition due to 
dehydration, malnutrition and electrolyte imbalance.   
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Emergency colorectal procedures requiring laparotomy are less likely to involve a primary 
anastomosis and are associated with higher morbidity and mortality due to the patients’ 
insufficiently optimized metabolic state 5,22. The surgeon has to manage unanticipated factors 
including septic shock as well as the technical demands of an oncologic resection without 
adequate work-up work up 23.  It is well reported that patients with stomas experience 
significant morbidity, poor quality of life, body dysmorphism and psychological distress 24,25. 
The risk factors predictive of poor outcome include age, peritonitis, systemic sepsis, tumour 
stage, cardiopulmonary co-morbidities, ASA grade and the presence of distant metastasis at 
presentation 4,21,26-29. These complicated presentations, which result in emergency surgery, are 
also associated with a longer hospital stay 30. 
Risk factors for mortality have been shown to be emergency surgery, age greater than 70 
years, weight loss greater than 10% within 6 months, neurological history, ASA score greater 
than zero or equal to three and preoperative renal failure. The mortality rate ranges from 
0.5% if no risk factors were present to 50% if all factors were present 31 .  
 
There was no in-hospital mortality in this cohort of patients with obstructed colorectal cancer. 
The author postulates that this is due to the fact that the study patients were younger in 
comparison to the world literature. Mortality and morbidity rates for emergency surgical 
decompression are 15-20% and 50%, respectively, as opposed to a mortality rate of 0.9-6% 
when patients undergo elective surgery 24,32. 
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Studies suggest that the resection rate is generally inferior in emergency surgery vs elective 
surgery (77% vs 85%) and that the oncological resection is inferior after emergency surgery 
when compared to elective surgery ( 60% vs 70%) 33. Resection rate in this series depended 
on the type of complication the patient presented with. Perforation had the highest resection 
rate at 97% and malignant fistula had the lowest resection rate at 32% with obstruction 
achieving a resection rate of 68%. 
 
Follow-up studies have shown that patients who present with these complications have a poor 
prognosis  33.Emergency operations are associated with decreased overall survival rate at 5 
years (75% versus 86% for elective intervention) 34. CCC presents at a more advanced stage 
and this also impacts the overall long-term prognosis 35. Five-year overall survival rate in this 
series was 85% for obstruction, 70% for perforation and 60% for malignant fistula  
 
5.1. Malignant Obstruction 
The definition of large bowel obstruction varies widely across the published literature, with 
no universally accepted description that stratifies the degree of obstruction requiring 
emergency surgery 36. Terms such as sub-acute obstruction, partial obstruction and sub-
occlusion further add to confusion 36. Aslar et al 37  defined obstruction as the combination of 
absolute absence of flatus or stool for at least 24 hours, abdominal distension and the 
presence of dilated colon on radiography. As patient information concerning symptoms at the 
time of presentation may be vague and the clinical signs subjective, this researcher defined 
obstruction as colorectal disease requiring emergency operative decompression at 
presentation thereby altering the conventional elective management of CRC. 
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The proportion of patients presenting with obstructing CRC differs worldwide. The reported 
incidence of complete obstruction ranges from 7 to 40% 24,36,38-40. Accepted as a surgical 
emergency, patients with complete large bowel obstruction are often managed at district 
hospitals. Factors such as the hospital location and the clinician’s definition of obstruction 
may in part explain the wide range in incidence reported in the literature 36,40,41. The 
proportion of patients presenting with obstructing CRC in this study was 20%, it fell within 
the range of published series and did not differ between races or sex. 
 
European studies reveal a mean age of presentation for malignant colon obstruction to be in 
the seventh decade of life 40,42.  In contrast, our study showed a younger age (mean 50.5 for 
Blacks, 55.6 for Indians, 58.4 for Coloureds and 64.7 for Whites) at presentation. In this 
cohort, Black patients were the youngest at presentation, mean age 50.55±15.87. The mean 
age at presentation for White patients was 64.7 years, which is similar to that in the Western 
literature which is quoted as 68-72 years (68 in males and 72 in females. 
 We believe that the younger age of presentation for this cohort is due to the fact that Black 
patients have been shown to present at a young age 36,43 and we have a larger number of 
Black patients in this study cohort.at 36.7%. 
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In this study almost 90% of the strictures were located at or distal to the splenic flexure 
24,44.Although some studies have demonstrated no differences in the incidence of right- and 
left-sided obstruction from CRC 45, others document the left colon to be the more common 
site of obstruction 38. Similarly, in this study, the left colon was involved more frequently, 
45% compared to 25%, in the proximal colon. Opinion suggesting that the splenic flexure is 
at greatest risk of obstruction due to acute angulation 46 was not confirmed in our study and 
that of Moolla et al 36; the most common site of obstruction in this study was the sigmoid 
colon and rectum both at 31%, with only a small number of  patients obstructing at the 
splenic flexure at 6%.  
 
CRC causing obstruction tends to be associated with a more advanced stage and with a 
greater incidence of liver metastases 38,46-48. This statistic was echoed in this study, although 
the predominance of stage IV disease was marginal at 34%. The optimal management of 
obstructing CRC remains controversial due to the paucity of randomized controlled studies. 
For obstructing colonic cancers, resection and diversion has been the mainstay of treatment in 
the unprepared colon, particularly for left-sided obstruction or in patients with peritonitis. The 
emergency management of acute left-sided colonic obstruction remains controversial. The 
following options are available (i) diverting loop colostomy or ileostomy and subsequent 
resection which can be in the form of two or three stage procedure, (ii) resection with end 
colostomy (Hartmann’s procedure), (iii) resection and primary anastomosis and (iv) SEMS 
49,50. 
 
 
 
49 
 
Colostomy is part of the staged management for left-sided colonic obstruction. During the 
first stage, the obstruction is relieved by the performance of a colostomy. At the second stage 
the tumour is resected and the colostomy is either reversed or, alternatively, the colostomy 
can be closed at a third stage. The advantage of offering a colostomy at presentation is to 
offer a lower risk surgery to decompress the colon and then allows for delayed staging and 
patient optimisation prior to the definitive resection 50. There is no evidence to suggest 
benefit in mortality with either primary anastomosis or staged procedures 50-52.  
 
While there is consensus concerning the emergency management of tumoral obstruction of 
the right and transverse colon, recent studies have demonstrated the potential safety of 
resection and primary anastomosis for right-sided lesions in unprepared bowel 49,53-55. The 
colonic segment containing the tumour and its mesentery are resected along with the entire 
dilated proximal colon as far as the ileo-caecal valve and  an ileo-colic (or ileo-rectal) 
anastomosis is made between non-distended intestinal segments 53. This method has the 
advantage of removing the unexplored proximal colon and any synchronous lesions 
(synchronous cancer is present in approximately seven% of cases), and of performing the 
anastomosis in the well-vascularized terminal ileum 53.  
 
Resection and anastomosis has remained controversial for left-sided tumours, however, there 
is increasing evidence that  primary anastomosis is the procedure of choice for left sided 
colonic obstruction 54,55. Treatment options for an obstructed left colon carcinoma, beyond 
the left flexure, includes resection of the left colonic segment with primary anastomosis, 
subtotal colectomy with primary anastomosis, and resection of the colonic segment involved 
with end colostomy and Hartmann’s procedure. Total or subtotal colectomy with primary 
anastomosis is advisable in patients with an obstructed left colon and dilated proximal colon. 
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Other indications requiring a total colectomy or subtotal colectomy include the presence of 
synchronous tumours, damage to the proximal colon preventing an anastomosis or caecal 
distention with threat of perforation 49,53. Total colectomy under these circumstances, is safe 
and the procedure of choice. 56  
 
Diverting colostomy and Hartmann’s resections retain a place in the emergency management 
of obstructive cancer, particularly in unstable patients. Other candidates for non-anastomotic 
surgery include patients in whom resection is thought to be unlikely due to morbidity or in 
patients with advanced colorectal cancer, classified as either locally irresectable, metastatic 
and or peritoneal carcinomatosis49,53. Malignant recto-sigmoidal obstruction usually requires 
an emergency surgical decompression by colostomy 24. Isolated stomas have a high 
complication rate, especially when performed as an emergency. The colostomy  may be 
permanent in patients with advanced disease or those with high-risk morbidity for further 
surgery 49,53.  A stoma, whether permanent or temporary, causes considerable psychological 
distress and has a significant impact on the patient’s daily life 24,57,58. 
 
Colonic stents were introduced in the 1990s and have been used for: (i) palliation for 
inoperable cancer, or for patients unfit for definitive surgery; or (ii) as a bridge to surgery. 
This procedure allows prompt relief of obstructive symptoms,  thus avoiding the need for 
emergency surgery or colostomy 24,59.The placement of a metallic stent in the colon was first 
published as a palliative measure in 1991 by Dohmoto60. Tejero and colleagues 59 modified 
the technique of stent placement using fluoroscopy.  
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Emergency surgery delays the commencement of chemotherapy. Hence, stent placement 
converts a major emergency procedure to a minor procedure thereby by allowing time to 
investigate and stage the disease, assessment for synchronous cancers, optimisation of 
comorbidities and nutrition and commencement of chemotherapy 61-63. This further allows for 
possible immediate restoration of intestinal continuity, thereby converting an emergency 
major procedure into an elective major resection without a stoma 49,53. 
 
Although colorectal SEMS are expensive, they have been established to be more cost-
effective than surgery as a result of the shorter hospital stay, shorter intensive care stay, 
decreased stoma rate and fewer complications 64-66. Also, these patients have a reduced 
recovery time, which is beneficial in such patients who have limited life expectancy 64-66.  
Recent systematic reviews and meta-analyses that reviewed the use of SEMS have showed 
variable technical and clinical success rates at comparable mortality rates 21,67-69. However, 
there have been conflicting results regarding complication rates of stents, namely perforation 
70-72. A systematic review of 88 studies with 1,785 patients  managed with SEMS in the acute 
setting, achieved a median clinical success rate for relieving obstruction of 92% and a 
perforation rate of 4.5 %  69. Comparatively, the overall success rate in our study was 87%, 
with a perforation rate of 4%. Failure of placement of SEMS in six patients (13%) in this 
study was due to inability by the endoscopic operator to pass the guide-wire safely across the 
stenosis.  
 
In the bridge-to-surgery setting, although the success rate of SEMS insertion has been 
reported to be as high as 93% 62,it is not always feasible. This may be due to technical 
inability to place the stent or lack of experienced operators. Colorectal stenting was utilised 
for palliation in 85% of the cohort and as a bridge to later surgical resection in 15%.  
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Colorectal SEMS-related complications may be classified as early or late. Early 
complications are defined as adverse events that develop within 30 days following SEMS 
insertion; late complications are those that occur thereafter. Major early complications 
include perforation (0% to 12.8%), stent migration (0% to 4.9%), re-obstruction (0% to 18%), 
pain (0% to 7.4%) and bleeding (0% to 3.7%) 62,73-77. Late complications include stent re-
obstruction (4.0% to 22.9%), stent migration (1.0% to 12.5%) and perforation (3.8%-6.9 
%)73,74,76,77. Covered SEMS area higher risk factor for migration (5.5% vs. 21.3% in the 
uncovered SEMS group) 78.  Most re-obstructions are caused by tumour ingrowth, although 
tumour overgrowth, faecal impaction and mucosal prolapse may also lead to stent re-
obstruction 73,79 . The re-obstruction rate tends to be lower for covered SEMS compared to 
uncovered ones. This is believed to be related to the lower rate of tumour ingrowth 66,73,78. 
 
The potential for tumour dissemination during the stent insertion procedure have been 
debated 62. The European Society of Gastrointestinal Endoscopy (ESGE) guidelines 
recommends SEMS placement as the preferred treatment for palliation of incurable CRC 
obstruction only62,77. It has been observed that the survival rate following potentially curative 
resection for obstructed cancer was worse than that in non-obstructed patients with 
comparable disease stage 47. The five-year survival in this study was 70%. Resection rate was 
influenced by the complication in this series. Malignant obstruction achieved a resection rate 
of 68%. 
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5.2. Malignant Perforation 
Perforation can either occur at the site of the cancer or proximal to a complete obstruction. It 
may present either as a free perforation, with peritoneal spillage, or as a localized perforation 
with an abscess. Perforation was the second most common complication (4%) in this study. 
Contrary to obstruction and fistula, perforation seemed to have an equal sex incidence. The 
clinical course of patients with malignant colorectal perforation depended on the onset of 
symptoms, as well as the patient’s nutritional status, age, and co-morbidities 33. Whereas 
patients with free perforation generally present in extremis, those with contained perforation 
tend to present in a more elective fashion, albeit with signs of infection, such as fever and 
leucocytosis 80. The predominant symptoms of perforation in this series were abdominal pain, 
abdominal distension and change in bowel habit.  
 
As seen in most series 39,47 the sigmoid colon was the most common site of the primary 
lesion; this incidence differs from  the disease distribution of CRC in the world literature and 
in South Africa 43, where the rectum is the most common site. The greater tendency for 
perforation in the sigmoid colon compared to other regions is unknown but may be related to 
the narrower diameter of the lumen in this portion of the colon. There was no difference in 
sex distribution. Similar observations have been made by others 39.  
 
The vast majority of the perforations were contained neoplastic perforations with no clinical 
signs of peritonitis, and all were confirmed at the time of surgery. The four percent rate of 
perforated CRC established in this study falls within the 2.6 – 10% reported in the literature 
38,39,47,81,82. Only 27% of patients required emergency surgery due to associated malignant 
large bowel obstruction. Tumour stages in perforated cancers are reported to be higher when 
compared to uncomplicated cancers 38,83. This finding was echoed in this study. Perforation 
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usually occurs near or at the site of the tumour, and it is associated with high postsurgical 
morbidity and mortality rates 39,47. This high morbidity and resultant mortality appears to 
decrease the 5-year survival rate by up to 20% 47,84.  
 
The operative treatment of CRC regardless of perforation or obstruction depends primarily on 
the location of the lesion and the operable fitness of the patient85,86. Our resection rate of 97% 
in this study attests to the fact that the operation of choice for perforated CRC is resection. 
Circumstances which may lead to the modification of the surgical procedure include the 
presence of a free perforation with clinical peritonitis or an obstruction in addition to 
perforation. This may cause dilatation of the proximal bowel thereby potentially affecting the 
safety of an anastomosis. A segmental colectomy, adhering to oncologic principles is feasible 
in the majority of cases with contained perforation 33. Subtotal colectomy with primary 
anastomosis may be considered for patients with left-sided perforation and associated 
obstruction resulting in distension and ischaemia of the proximal colon33,87. Otherwise, 
resection of the neoplasm with proximal colonic diversion and a Hartmann’s procedure may 
be indicated if there is local peritonitis. All patients in whom the tumour was resectable in 
this series, however, were managed by colectomy and primary anastomosis.  
 
In the study by Alvarez et al 38 the mortality rates for perforated lesions was 29%. The main 
causes of death were sepsis and MODS.The long-term outcome depends on other factors such 
as disease stage, presence of poor prognostic factors, physiological status of the patients and 
not the perforation status .Therefore provided these patients with perforated CCC receive the 
same oncologic resection as non-perforated CRC, the short and long-term outcome should be 
quite similar 
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There was no in-hospital mortality. The zero mortality rate in this study is striking when 
compared to the reported 5-40% in-hospital mortality for perforated colorectal cancer in other 
series 39,45,47,80,81,83,84,88,89. The zero mortality in this series may be explained by the fact that 
patients in this study did not undergo emergency laparotomy except when there was an 
associated obstruction and, even under these circumstances; the reason for the emergency 
procedure was the presence of colonic obstruction. Another possible explanation for the 
extremely low operative mortality may be that all these patients were attended to timeously at 
their local hospital and were thus not physiologically compromised from delay in 
presentation. It is possible that patients with free perforation, and thus with severe 
physiologic compromise, may have been selected out and demised prior to arrival. This low 
mortality equivalent to findings in the study by Zielinski et al reporting on contained 
perforation 80. This author postulates that these are due the contained neoplastic perforation, 
thus avoiding peritonitis. 
 
 
In contrast to obstructing CRC which has been repeatedly shown to be associated with 
advanced disease 38,48, reports on perforated CRC have yielded conflicting results. Some 
studies have suggested a greater incidence of metastatic disease, more advanced disease 
stage, and greater residual tumour burden at the time of presentation for perforated colorectal 
cancer 38,47,80,81,90. Other studies have shown perforated cancers to be less advanced compared 
to obstructing cancers 38,39. The reason for this difference may be related to a presumed 
longer time required to cause complete obstruction, resulting advanced stage at diagnosis, as 
opposed to the shorter time needed for tumour necrosis resulting in perforation 39.  
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Our R-0 resection rate compares favourably with other studies reporting 62–68% in patients 
with perforated CRC80. This author shares the assertion by Zielinski et al that, whether or not 
the malignant process extends to the circumferential margin is dependent not on the 
perforation itself but rather on the extent to which the malignant process has permeated 
through the bowel wall along with the necrosis as it causes the perforation 80.  
The long-term prognosis of patients with neoplastic perforation is unclear in the literature, 
some studies report a negative effect on patient outcome 39, while other studies report 
perforation as a positive predictive feature 39,91,92. These conflicting data stem from the 
tendency of previous studies to not clearly differentiate between free and contained 
perforation or between neoplastic and proximal perforation.  
 
Two studies have reported a poorer survival and higher recurrence rates with perforation 
proximal to the tumour compared to non-perforated tumours, suggesting that tumour cell 
spillage into the peritoneal cavity may result in peritoneal dissemination and  negative 
influence on the patients’ survival 39,80. Survival seems to be related to the cause and the site 
of the perforation in relation to the tumour itself. Consensus dictates that this patient 
population should receive aggressive surgical intervention and appropriate adjuvant 
oncologic therapy 39. Another series has suggested that, when the immediate post-operative 
morbidities have been corrected and, if adequate oncological surgery has been performed, the 
long-term outcomes are similar to those of non-perforated controls 39,45,80,93. Therefore, an 
aggressive surgical approach based on adequate oncologic resection principles is indicated. 
This further suggests that perforation with tumour spillage into the contained area of 
perforation, if it occurs, does not reach a degree that results in tumour implantation and as 
such is not an indicator of poor prognosis 39,45,80,93.  
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In this series resection rate was dependent on the type of complication as well as tumour site. 
Patients with perforation had the highest resection rate at 97%. The reported overall five-year 
survival of 85% is encouraging. The best survival rate was achieved in patients who 
presented with perforation.  
 
5.3. Malignant Fistula 
A fistula is an abnormal epithelium-lined connection between two epithelial surfaces. The 
most common cause of colovesical fistulae is diverticular in origin, followed by malignancy 
and Crohn’s disease94-96.Commonmalignancies resulting in rectovaginal fistulae include those 
of the cervix, rectum, uterus, or vagina97,98. In the context of malignant fistula, invasive 
tumour erodes into luminal structures such as the vagina, resulting in fistulisation97. Fistulae 
may also occur following radiation treatment98. The added combination of neo-adjuvant 
therapy and surgery render the tumour bed or site of anastomosis particularly vulnerable to 
the development of rectovaginal fistula98. The most common tumour associated with 
malignant fistula is CRC. However, colon cancer alone has a much lower incidence of fistula 
formation, reported as 0.5-0.6 %94,96,99-102. The 1.5% fistula rate in this series compares 
favourably with the literature. Colovesical fistulae most commonly occur following sigmoid 
colon malignancy94,99. They occur more frequently in  men as the interposing uterus in 
women is protective94,99.Indeed, many women who present with colovesical fistula, have had 
a previous hysterectomy94,99. Rectovaginal fistulae resulting from colorectal or 
gynaecological malignancy typically occur proximal to the sphincter97. 
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Presenting symptoms most commonly arise from the urinary tract. The classical findings are 
pneumaturia and faecaluria95,96,103. Other symptoms include dysuria, frequency of micturition, 
haematuria and a combination of these 96,103. Diagnostic verification of colovesical fistula is 
necessary not only to establish the presence of the fistula but also the anatomic region of the 
colon involved in order to guide subsequent surgery95,96. Options include CT scan, 
cystoscopy, cystography, contrast enema and colonoscopy95,96. 
 
The management of both colovesical and rectovaginal fistulae is determined by the 
underlying aetiology as well as the resectability of the tumour. In the context colovesical 
fistulae, surgical intervention is essential to avoid complications such as cystitis and 
pyelonephritis 103. The management options colovesical fistulae described in the literature 
include conservative management, resection of the bladder and the colon with or without 
interposition of the omentum and diverting stoma 94,101.Diverting colostomy can be used as a 
covering stoma prior to resection of the fistula or can be used as permanent colostomy in 
patients who are considered not fit for definitive management and are considered for 
palliative treatment 94,101.  
 
There is scarce literature describing the management of malignant colovesical fistulae and the 
available literature make no comment of the use of flaps following resection and repair of the 
respective hollow organs 99-102,104.We do not use flaps in our unit. Surgery is, for the most 
part, determined by the site and the aetiology of the colonic lesion 94.Resection of the 
diseased segment is an essential component in achieving cure99.  Definitive surgical options 
include either a resection with primary anastomosis, primary anastomosis with a temporary 
diverting stoma, Hartmann’s procedure or 3-stage procedures 99,103. A single stage resection is 
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recommended as the treatment of choice for uncomplicated colovesical and rectovaginal 
fistula from colonic carcinoma94,101,103.  
 
The first step to evaluate the surgical correction of these fistulae is addressing resectability of 
the primary97. Typically the resection incudes an en-bloc resection of the fistula94,96,97. The 
resulting defect in the secondary organ should be closed primarily 103. In irresectable disease 
a proximal diverting stoma is recommended to improve quality of life73.  
 
In colovesical fistulae, there needs to be local resection of the bladder of the bladder involved 
95. Should resection of the bladder potentially reduce the overall capacity, considerations 
should be given to reconstructive procedures to provide adequate bladder capacity continence 
95. For more extensive tumours, pelvic exenteration is another option104.A single stage 
procedure may not be feasible when there is extensive inflammation, abscess, complex 
fistulae, radiation, irresectable malignancy or poor surgical fitness (94). Conventionally, the 
management of colovesical fistula has been performed as a three stage procedure, namely, 
diverting colostomy, repair of the fistula and closure of colostomy 95,103.More recently 
colovesical fistulae are repaired in a single-stage procedure has been reported with 
success94,95,103. 
 
Controversy remains over the decision to perform a single stage versus multistage procedure 
to correct colovesical fistulae. The presence of previous radiation, intestinal obstruction, 
abscess, concurrent reconstruction of the bladder and an unprepared bowel all dictate that the 
intestinal tract should be defunctioned prior to attempted repair 95. Malignant colovesical and 
rectovaginal fistulae may be associated with colorectal stenosis. The endoscopic management 
of a colorectal stenosis with an associated fistula may involve the use of a SEMS 94,102;more 
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specifically, a covered SEMS 102. This technique has the advantage of securing the device to 
the stenotic bowel segment preventing movement as well as covering the opening of the 
fistula, even in the presence of neoplastic, fragile tissue102. 
 
Where a stent cannot be placed due to technical reasons, a colostomy becomes the only 
feasible option suitable. Palliative surgical options for both colovesical and rectovaginal 
fistulae, in patients who are either unfit or do not wish to undergo major resection surgery or 
in the presence of irresectable disease, included a defunctioning ileostomy or colostomy 
94,98,99,103. The use of stents for the palliation of malignant fistula has been described105,106. 
The procedure is only feasible if the fistula is associated with a stricture 
 
Malignant fistula had the lowest resection rate at 32%. The R0 resection rate was 78% in this 
patient group. Reportedly invasion of the bladder from CRC does not carry a poorer 
prognosis,so long as an en-bloc resection of colon and bladder is performed101.The 5-year 
survival with macroscopic tumour clearance reported in the literature is 56-62% 101.Five-year 
survival for malignant fistula in our cohort was the poorest at 60% compared to the other 
neoplastic complications in this series. 
  
61 
 
 
5.4. Limitations 
The limitations of this study are that the duration of follow-up was very poor. Follow-up is a 
major problem in our geographic society, with socio-economic status and difficulties with 
transport for face-to-face follow-up being major drivers of the poor follow-up. Also, it is 
likely that other patients with a perforated colorectal cancer were managed locally and might 
have been too ill to be sent to our regional units.  
 
The strength of the study is that it specifically addresses contained perforation of colorectal 
cancer as opposed to free perforation and it differentiates direct neoplastic perforation from 
proximal perforation. This is an improvement on previous studies, whose weakness was 
failure to differentiate between free and contained perforation as well as neoplastic and 
proximal perforation. Moreover, this work is the first report to address this condition in South 
Africa and in Africa.  
 
Follow-up was limited as some patients were lost to follow-up. 
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CHAPTER 6 
CONCLUSIONS 
 
The prevalence of complicated colorectal cancer in our setting is similar to that reported in 
the literature. The prevalence is the same across all population groups and the sex incidence 
is similar, but the age at presentation is younger in Blacks. The site distribution varied 
according to the complication, with obstruction associated more frequently with left-sided 
disease and fistula involving the sigmoid and rectum.  
 
Full oncological resection was performed in the majority of patients with malignant 
obstruction and perforation. The majority of patients presenting with malignant fistula 
underwent a diverting colostomy. The resection rate was dependent on the type of 
complication. The oncological resection rate was better for malignant perforation and 
obstruction than malignant fistula. The fistula population also had a worst survival rate. 
Patients who underwent resection had a zero in-hospital mortality rate. Contained perforation 
rarely resulted in clinical peritonitis in our patient cohort. We feel this contributed to the zero 
post-operative mortality. 
 
The perforation status did not impact on long-term outcome. As such patients with 
obstruction and perforation who had oncological resections should have similar short and 
long-term outcomes as non-complicated colorectal cancer. Patients with malignant fistula 
appeared to have the worst outcome in this study group. Earlier presentation of CCC (and 
CRC in general) in our setting in Black patients highlights the need for more research in 
developing countries. In the absence of randomized controlled trials, intra-operative 
management will remain at the discretion of the operating surgeon.  
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Stenting at centres with expertise is an attractive alternative for obstruction and for fistula, 
however, patient selection remains key in deciding on whether or not to use a stent. 
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